Veranex, a Raleigh, NC-basedmedical technology company, acquired Devicia, a Stockholm, Sweden-based provider of clinical expertise, also Clarvin, a Stockholm, Sweden-based provider of strategic guidance in regulatory affairs and quality assurance.
The amount of the deals was not disclosed.
With the acquisition, Veranex will further expand its European reach and build regulatory, clinical, and quality service segments. The group of companies adds three locations across Europe and the U.S. to Veranex’s global footprint.
Led by CEO Åsa Runnäs, Clarvin is the regulatory consultant for medical device and IVD manufacturers that guides and supports in every aspect of regulatory affairs and quality assurance processes. The team identifies customized regulatory intelligence solutions within rapidly emerging technologies and the evolving regulatory landscape.
Led by CEO Elisabeth Liljensten, Devicia is a consulting firm offering clinical expertise for medical devices, supporting clients throughout the life cycle of medical device and IVD.
Led by CEO David Dockhorn, Veranex is a tech-enabled service provider dedicated to the medical technology industry. Offering guidance from concept to commercialization and across the development continuum, the company enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time, while its comprehensive solutions unify and streamline the entire development process.
Veranex is backed by Summit Partners, Accelmed, and Lauxera Capital Partners.
FinSMEs
16/10/2022